Prabha N. Ibrahim

Dr. Ibrahim joined Afferent as chief technology officer in November 2015. She brings more than 23 years of experience in drug discovery and development, having served in a number of senior leadership positions at Plexxikon Inc., most recently as senior vice president of chemistry and non-clinical development. During her tenure, Dr. Ibrahim played a key role in Plexxikon’s scaffold-based drug discovery efforts for a variety of protein family targets. She was instrumental in the discovery and development of Zelboraf®, the company’s first oncology drug approved for metastatic melanoma, and pexidartinib, which is currently in Phase 3 clinical trials for pigmented villonodular synovitis (PVNS). Earlier in her career, Dr. Ibrahim held the positions of senior research scientist and group leader at CV Therapeutics, Inc., and research scientist at Amgen. She earned her Ph.D. degree in organic chemistry from the University of Victoria and was a Welch Foundation Fellow at Rice University. She received her M. Sc. Degree from The American College, Madurai, India, and her B.Sc. degree from RDM College, Sivaganga, India. Dr. Ibrahim is an inventor name on more than 130 patents, and an author of 28 scientific publications.